{"organizations": [], "uuid": "332ecb59417dd46f49f4befaaec86f1280035c46", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kura-oncology-announces-new-patent/brief-kura-oncology-announces-new-patent-for-tipifarnib-in-hematologic-malignancies-idUSFWN1S90LF", "country": "US", "domain_rank": 408, "title": "Kura Oncology Announces New Patent For Tipifarnib In Hematologic Malignancies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.414, "site_type": "news", "published": "2018-05-02T19:40:00.000+03:00", "replies_count": 0, "uuid": "332ecb59417dd46f49f4befaaec86f1280035c46"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kura-oncology-announces-new-patent/brief-kura-oncology-announces-new-patent-for-tipifarnib-in-hematologic-malignancies-idUSFWN1S90LF", "ord_in_thread": 0, "title": "Kura Oncology Announces New Patent For Tipifarnib In Hematologic Malignancies", "locations": [], "entities": {"persons": [], "locations": [{"name": "hematolo", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "kura oncology inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "kura oncology announces new patent for tipifarnib in hematologic malignancies", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - Kura Oncology Inc:\n* KURA ONCOLOGY ANNOUNCES NEW PATENT FOR TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES\n* KURA ONCOLOGY INC - BIOMARKER-ENRICHED DATA FROM ONGOING PHASE 2 TRIALS OF TIPIFARNIB IN HEMATOLOGIC MALIGNANCIES EXPECTED IN H2 OF 2018\n* KURA ONCOLOGY INC - PATENT EXPANDS PROTECTION FOR TIPIFARNIB IN U.S., PROVIDES EXCLUSIVITY IN CERTAIN CXCL12-EXPRESSING CANCERS TO 2037 ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T19:40:00.000+03:00", "crawled": "2018-05-02T14:58:02.000+03:00", "highlightTitle": ""}